[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
November 9, 2005

Biomedical Journals Probe Peer Review

JAMA. 2005;294(18):2287-2288. doi:10.1001/jama.294.18.2287

Chicago—A string of controversies in recent years over pharmaceutical companies withholding information about drug risks and researchers failing to disclose financial ties with drug companies has shaken the confidence of clinicians and patients alike. Last year, officials questioned whether data indicating that certain drugs (such as Merck & Co’s pain relief drug rofecoxib and GlaxoSmithKline’s paroxetine, an antidepressant) pose risks for patients were known by the companies but not reported, events that highlighted the need for greater transparency in drug trials.